Does Minnesota Medicaid cover GLP-1s for weight loss?

Minnesota Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The published threshold is: 30 or more with no risk factor, or 27 or more with a weight-related comorbidity such as hypertension, type 2 diabetes or dyslipidemia; 12–17 year olds need 30 or more and a body weight above 60 kg. On what has to be tried or preferred first: A reduced-calorie diet under way, or ongoing care from a registered dietitian nutritionist, plus a regimen of increased physical activity unless a comorbidity makes it inadvisable, and no other weight-loss drug at the same time. Last checked 2026-09-05.

What the prior authorization asks for

BMI threshold: 30 or more with no risk factor, or 27 or more with a weight-related comorbidity such as hypertension, type 2 diabetes or dyslipidemia; 12–17 year olds need 30 or more and a body weight above 60 kg
Tried first: A reduced-calorie diet under way, or ongoing care from a registered dietitian nutritionist, plus a regimen of increased physical activity unless a comorbidity makes it inadvisable, and no other weight-loss drug at the same time.
To keep it: 5% weight loss for adults, or a 5% reduction in baseline BMI at 12–17, and past 18 months the loss has to be maintained
Age: The age on the FDA label of the drug requested
Approval runs for: 6 months, then 12-month renewals

The covered list runs Saxenda, Wegovy, Zepbound, Contrave, Xenical, orlistat and the phentermine class. Phentermine and the other older agents get three months and cannot be renewed.

Both tools fill from these criteria rather than from a template — a prior authorization for Minnesota, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.

Whatever Minnesota decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.

If you end up paying cash

The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:

Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
Noom Med$249/moverified 2026-09-22compounded, not FDA approved
Found$289/moverified 2026-09-22compounded, not FDA approved

Go to Strut Health, the cheapest verified route ↗

Every verified price, ranked and segmented →

Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.

The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.

Other states with criteria of their own

Source: Minnesota Health Care Programs PA criteria: Anti-Obesity Medications , effective 2026-08-01. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Minnesota can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.